Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eastwood Bio-Medical CanadaTSXV:EBM +1.02%25 Days Payable is 325.67 as of Apr. 2026, which is 792% above its 10-year median of 36.50. GuruFocus rates TSXV:EBM with a GF Score™ of 25/100 and a GF Value™ of C$0.53 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 701 Biotechnology companies, Eastwood Bio-Medical Canada ranks better than 60.2% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:EBM vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Eastwood Bio-Medical Canada's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eastwood Bio-Medical Canada Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eastwood Bio-Medical Canada's Days Payable distribution charts can be found below:
* The bar in red indicates where Eastwood Bio-Medical Canada's Days Payable falls into.
Eastwood Bio-Medical Canada Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eastwood Bio-Medical Canada (TSXV:EBM) has a Days Payable of 325.67 as of Apr. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Eastwood Bio-Medical Canada and its competitors. This is 792% above median its historical median of 36.50. Over the past decade, Eastwood Bio-Medical Canada's Days Payable has ranged from 7.60 to 175.61. According to the industry distribution chart, Eastwood Bio-Medical Canada ranks #279 out of 701 companies in the Biotechnology industry, placing it in the top 39.8%.
Is Eastwood Bio-Medical Canada's Days Payable too high?
Eastwood Bio-Medical Canada's current Days Payable of 325.67 is 792% above median its 10-year median of 36.50. Over the past 10 years, this metric has ranged from a low of 7.60 to a high of 175.61. The Biotechnology industry median Days Payable is 113.36. Eastwood Bio-Medical Canada's value of 325.67 is 187.3% above this industry median. Based on the distribution chart, Eastwood Bio-Medical Canada ranks #279 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Eastwood Bio-Medical Canada has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eastwood Bio-Medical Canada's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eastwood Bio-Medical Canada ranks #279 out of 701 companies for Days Payable. This puts Eastwood Bio-Medical Canada in the upper half of its industry. The industry median Days Payable is 113.36. Eastwood Bio-Medical Canada's value of 325.67 is 187.3% above this benchmark. Historically, Eastwood Bio-Medical Canada's own Days Payable has ranged from 7.60 to 175.61 over the past decade. While the company's 10-year median is 36.50 vs. the industry median of 113.36, Eastwood Bio-Medical Canada has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eastwood Bio-Medical Canada's current Days Payable of 325.67 is 187.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Eastwood Bio-Medical Canada and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eastwood Bio-Medical Canada's current Days Payable is 325.67, which is 792% above median its own 10-year median of 36.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eastwood Bio-Medical Canada stock overvalued right now?
Based on GuruFocus' analysis, Eastwood Bio-Medical Canada (TSXV:EBM) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.53, compared to a current price of C$0.99 — trading 86.8% above its estimated fair value. The current Days Payable is 325.67, which is 792% above median its 10-year median of 36.50 and 187.3% above the Biotechnology industry median of 113.36. Eastwood Bio-Medical Canada's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Eastwood Bio-Medical Canada (TSXV:EBM), the current Days Payable is 325.67 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eastwood Bio-Medical Canada (TSXV:EBM) Overvalued in 2026?
Based on GuruFocus' analysis, Eastwood Bio-Medical Canada stock appears to be overvalued.
The current stock price of C$0.99 is trading 86.8% above its estimated GF Value™ of C$0.53.
GuruFocus considers Eastwood Bio-Medical Canada to be Significantly Overvalued.
Key valuation signals for TSXV:EBM:
Days Payable: 325.67 (792% above median its 10-year median of 36.50)
GF Value™: C$0.53 vs. price of C$0.99 (86.8% above fair value)
Industry Position: 187.3% above the Biotechnology median (#279 of 701)
No single metric tells the full story. See the TSXV:EBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eastwood Bio-Medical Canada Inc is a Canadian company engaged in the development and commercialization of safe and effective treatment for non-insulin dependent diabetes mellitus. The company is engaged in natural health supplement distribution company. It has its geographic presence in U.S., Canada and Asia. The company generates maximum revenue from Asia.
25GF Score
Get the complete analysis for TSXV:EBM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:EBM has been successfully added to your 
